OTLK earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -0.98. Updated 2026-07-23.
Outlook Therapeutics (OTLK) Research Hub
Outlook Therapeutics (OTLK) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.66 USD (+2.50%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.98, market cap 0.05B. This hub links to the full technical, earnings and options research available for OTLK.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.66 USD (+2.50%) |
| 52-week range | 0.6115 USD – 1.88 USD |
| Trend regime | Range |
| 14-day RSI | 27.1 (Oversold) |
| Trailing P/E | -0.98 |
| Market cap | 0.05B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for OTLK
Covered Call on OTLK: how it works, illustrative setup around the real 0.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OTLK: how it works, illustrative setup around the real 0.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OTLK: how it works, illustrative setup around the real 0.66 USD price, max profit/loss, breakeven and when to use it. Educational.
OTLK technical analysis: range, last 0.66 USD, RSI 27.1, 52w range 0.6115 USD–1.88 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OTLK in?
Outlook Therapeutics (OTLK) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OTLK in an uptrend or downtrend?
As of 2026-09-11, OTLK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OTLK's trailing P/E ratio?
OTLK's trailing P/E is -0.98, with a market cap of 0.05B. See the earnings research page for full valuation detail.
When does OTLK next report earnings?
OTLK is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.09 USD.